RESPINOR is developing a novel, non-invasive, ultrasound-based medical device for continuous diaphragm monitoring, the main breathing muscle. RESPINOR’s technology is the winner of Horizon 2020 funding both in phase I and II. Our technology has a broad range of potential benefits and represents a technology platform for applications in critical care and other areas of respiratory medicine.
COVID-19 is deeply disrupting our health and socio-economic systems and provoking severe shortages of MV capacity, prompting an urgent need for accelerating the development and spread of technologies that can reduce the strain on these resources. RESPINOR DXT – is a breakthrough ultrasound technology that provides an objective and continuous measure of diaphragm function, our main breathing muscle, hence improves clinical decision-making in critically ill patients’ weaning readiness from mechanical ventilation.